“Dexamethasone reduces death risk in severe COVID-19 patients hospitalised in intensive care whether under oxygen or on respirator according to a UK research which findings were not published yet,” announced member of the Scientific Committee on the Fight against Coronavirus and Specialist in pharmacology Anis Guellouz.
In a statement to the TAP, Guellouz said that Clinical trials involving 11,500 patients were performed in 170 hospitals, 4,000 patients only required oxygen while Dexamethasone was helpful in treating a further 2,200. Other protocols of care, including chloroquine, were used for other patients.
“These trials revealed that approximately 5,000 deaths were avoided in the UK among critical COVID-19 patients treated with dexamethasone, ” he added.
This protocol of care, which proved to be very effective, was used in Tunisia for the sake of research and experimentation.
“The drug is available in pharmaceutical laboratories in Tunisia or through the channels of distribution of the Central Pharmacy,” he said.
Source: TAP
Algerian firmness on questions of memory Algerian President Abdelmadjid Tebboune reaffirmed Algeria's determination concerning the…
The United Nations Department of Peace Operations has announced that Major Ahlem Douzi, who serves as…
British Minister of State for the Middle East, North Africa, South Asia, Commonwealth and United…
Security forces in the National Guard district of Thala, Kasserine region, apprehended an individual from…
Budding geniuses have an appointment with the 2023 Nobel Prize in Chemistry, Mongi Bawendi. The…
The Free Destourian Party revealed, in a press release, issued yesterday Monday, that it “will lodge…
This website uses cookies.